Combination of chemotherapeutic agents and biological response modifiers (immunotherapy) in triple-negative/Her2(+) breast cancer, multiple myeloma, and non-small-cell lung cancer

2Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Hypothesis: Biological response modifiers (immunotherapy) in combination to chemotherapy are superior to that of chemotherapy in treatment of breast cancer (triple-negative/HER-2 (+)), multiple myeloma, and non-small-cell lung cancer. Methods: This review article consists of a total of eighteen independent randomized controlled clinical trials ranging from phases one to three. Patients were randomly selected for immunomodulatory treatment or chemotherapy and assessed for a specific mutation expression that the immunomodulatory agent targets. Kaplan–Meier plots, swimmer plots, and bar graphs depict overall/progression-free survival, objective response, and clinical response rates. The data collected was assessed by using 95% confidence interval and a p value of 0.05. Patients were treated until disease progression. Results: Biological response modifiers (immunotherapy) resulted in significantly longer median progression-free survival in PD-L1-positive breast cancer (7.5 months compared to 5.0 months in control group), multiple myeloma (60.7% compared to 26.9% in the daratumumab and placebo groups, respectively), and in non-small-cell lung cancer (median progression-free survival was 10.3 months in the pembrolizumab group compared to 6.0 months in the chemotherapy group): higher complete responses in multiple myeloma (79% and 66% in the elotuzumab and control groups, respectively) and lower disease progression in PD-L1-positive non-small-cell lung cancer (62.1% of pembrolizumab versus 50.3% of chemotherapy patients had no disease progression at 6 months). Conclusion: Combination biological response modifiers (immunotherapy) and chemotherapy displayed benefit in overall/progression-free survival, response rate, duration of response, clinical benefit, and invasive disease-free survival in triple-negative/HER2-2(+) breast cancer, multiple myeloma, and non-small-cell lung cancer.

Cite

CITATION STYLE

APA

Morse, W., Nawaz, H., & Choudhry, A. A. (2022, December 1). Combination of chemotherapeutic agents and biological response modifiers (immunotherapy) in triple-negative/Her2(+) breast cancer, multiple myeloma, and non-small-cell lung cancer. Journal of the Egyptian National Cancer Institute. Springer Science and Business Media Deutschland GmbH. https://doi.org/10.1186/s43046-022-00159-8

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free